Ferring Pharmaceuticals announced today that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland.   Over the next three years, Ferring will invest approximately 30 million CHF in the new Ferring Biotech Centre, which will incorporate discovery and development capabilities for monoclonal antibodies as well as biologics manufacturing capabilities.   ...